Grants for Unrestricted - Science and Technology

This funding opportunity is designed for research institutions and organizations affiliated with the Rocky Mountains Cooperative Ecosystems Studies Unit to investigate remote sensing techniques for monitoring dissolved organic matter in water, ultimately improving water quality management across the United States.

This funding opportunity is designed for partners within the Californian Cooperative Ecosystem Studies Unit to support research on climate-driven range shifts by providing training, facilitating workshops, and conducting data synthesis efforts.

U.S. Embassy Bern invites proposals for programs that strengthen cultural ties between the United States and Switzerland or Liechtenstein through cultural and exchange programming that highlights shared values and promotes bilateral cooperation and dialogue. All programs must include an American cultural element, or connection with (a) U.S. expert/s, organization/s, or institution/s in a specific field that will promote increased understanding of U.S. policy and perspectives. The PDS Small Grants Program is open to applications from Swiss, Liechtenstein, and U.S. organizations and individuals. We especially encourage and will prioritize applications from alumni of U.S. State Department Exchange Programs who are residents of Switzerland or Liechtenstein. Priority Program Areas: 1. Recognizing and countering disinformation and misinformation 2. Diversity, equity, inclusion, and accessibility, with a special focus on: 2.1. Women and girls, in all their diversity, in STEAM fields 2. 2.Increasing visibility, equity, inclusion, and accessibility of underrepresented groups in Switzerland and Liechtenstein, including immigrants, migrants, refugees, and asylees 3. Promoting mobility and knowledge transfer of apprenticeships between Switzerland/Liechtenstein and the United States 4. Strengthening entrepreneurship and economic collaboration between the United States and Switzerland with an emphasis on emerging and women entrepreneurs and business students Participants and Audiences: 1. Swiss and Liechtenstein residents 2. Underrepresented groups 3. Swiss and Liechtenstein youth aged 16 to 25 4. Emerging and established professionals and leaders in the priority program areas mentioned above Applicants should read the full description of the statement, attached here or on our website: https://ch.usembassy.gov/embassy/jobs/proposals/

This funding opportunity is designed for partners affiliated with the Colorado Plateau Cooperative Ecosystem Studies Unit to conduct research on drought conditions and sagebrush habitat resilience in dryland ecosystems.

This grant invites organizations and companies to collaborate on innovative health solutions aimed at reducing disease and mortality rates in low-and-middle-income countries.

This program provides financial assistance to livestock operators affected by infrastructure damage from wildfires and associated flooding, helping them with reconstruction costs.

This funding opportunity is designed for research institutions affiliated with the Southern Appalachian Mountains CESU to study climate adaptation in oak-dominated ecosystems and their impact on wildlife, with a focus on species distribution and resource management.

The FY24 ALSRP Pilot Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ALS. Projects may range from phase 1 to small-scale phase 2 trials and should aim to de-risk and inform the design of more advanced trials by investigating safety, feasibility, biomarker application, and therapeutic efficacy in relevant patient populations. Clinical trials may be designed to evaluate promising drugs, biologics, or devices with anticipated therapeutic impact that is supported by strong scientific rationale and existing preliminary studies and/or preclinical data. Clinical trials aimed to improve aspects of patient care and ALS symptom management are also applicable to this award mechanism.Funding from this award mechanism must support a clinical trial. A clinical trial is defined as a research study in which one or more study participants are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. For more information, a Human Subject Resource Document is provided at https://cdmrp.health.mil/pubs/pdf/Human%20Subjects%20Resource%20Document_DEC2022.pdf. Principal Investigators (PIs) seeking funding for a preclinical research project should consider one of the other FY24 ALSRP program announcements being offered. Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.Projects proposing a therapeutic intervention (drug, biologic, and/or device) must incorporate biomarkers specific to the intervention into the trial design. Applicants must clearly describe a biomarker-driven approach and its potential to de-risk and improve the design of anticipated later-stage trials. For further description, see Attachment 13, Biomarker Statement. Biomarker development and characterization can include target engagement biomarkers, pharmacodynamic biomarkers to measure the biological effect of an investigational therapeutic, and/or predictive/cohort-selective biomarkers that indicate whether a specific therapy will be effective in an individual patient or patient subgroup.Key aspects of the FY24 ALSRP Pilot Clinical Trial Award mechanism include:Impact: Potential impact from a pilot clinical trial is not whether an intervention is ready at the conclusion of the trial, but rather if the outcomes will improve and accelerate future larger trials or clinical care and symptom management. Applications submitted to this award can have outcomes that focus on specific subpopulations of ALS patients or potentially even individual patients.Biomarker-Driven Interventions: Therapeutic outcomes should directly and substantially de-risk and inform the design of anticipated later-phase trials of the intervention under investigation.Clinical Care: Improving aspects of clinical care and symptom management should have near-term impact on patients. All interventions must offer significant potential impact for individuals affected by ALS; however, this may include just specific subpopulations or potentially even individual patients.Employing Community Collaborations to Optimize Research Impact Is Required. Research funded by the FY24 ALSRP Pilot Clinical Trial Award should be responsive to the needs of people with ALS, their families, and/or their care partners. Research teams are therefore required to establish and utilize effective and equitable collaborations and partnerships with Community members to maximize impact potential of the proposed research. These collaborations are expected to facilitate accessible, efficient, and humane clinical trials. Applications to the FY24 ALSRP Pilot Clinical Trial Award must name at least one Community partner (e.g., person with ALS, family member and/or caregiver, representative of a community-based organization) who will provide advice and consultation throughout the planning and implementation of the research project. Scientific researchers and Community members will collaborate and contribute equitably on all aspects of the project, which may include needs assessment, planning, research intervention design, implementation, evaluation, and dissemination. Interactions with other team members should be well integrated and ongoing, not limited to attending seminars and semi-annual meetings. Examples for implementing collaborative research approaches include:Person Living with ALS, Family Member, and/or Caregiver: The research team includes a person with ALS, their family member, or caregiver (past or present) as a project advisor who will provide advice and consultation throughout the planning and implementation of the research project.Partnership with a Community-Based Organization: The research team establishes partnerships with at least one Community-based organization that provides advice and consultation throughout the planning and implementation of the research project. Community-based organizations may include advocacy groups, service providers, policymakers, or other formal organizational stakeholders.Community Advisory Board: A Community advisory board is composed of multiple Community stakeholders and can take many forms, from a board of people with ALS, their family members, or caregivers to a coalition of Community-based organizations or any combination thereof. As with people living with ALS and organizational partners, the Community advisory board provides advice and consultation throughout planning and implementation of the research project.Clinical Trial Start Date and Intervention Availability: The proposed clinical trial is expected to begin no later than 12 months after the award date or 18 months after the award date for Food and Drug Administration (FDA)-regulated studies. The application should demonstrate the documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study.Study Population: The application should demonstrate the availability of and access to a suitable patient population that will support a meaningful outcome for the study. The application should include a discussion of how accrual goals will be achieved, as well as the strategy for inclusion of women and minorities in the clinical trial appropriate to the objectives of the study.Research Personnel and Environment: The application should demonstrate the study teams expertise and experience in all aspects of conducting clinical trials, including appropriate statistical analysis, knowledge of FDA processes (if applicable), and data management. The application should include a study coordinator(s) who will guide the clinical protocol through the local Institutional Review Board (IRB) of record and other federal agency regulatory approval processes, coordinate activities from all sites participating in the trial, and coordinate participant accrual. The application should show strong institutional support and, if applicable, a commitment to serve as the FDA regulatory sponsor, ensuring all sponsor responsibilities described in the Code of Federal Regulations, Title 21, Part 312 (21 CFR 312), Subpart D, are fulfilled.Statistical Analysis and Data Management Plans: The application should include a clearly articulated statistical analysis plan, a power analysis reflecting sample size projection that will answer the objectives of the study, and a data management plan that includes use of an appropriate database to safeguard and maintain the integrity of the data. If FDA-regulated, the trial must use a 21 CFR 11-compliant database and appropriate data standards. For more on data standards, see https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ FormsSubmissionRequirements/ElectronicSubmissions/UCM511237.pdf.Transition Plan: Applications should include a transition plan (including potential funding and resources) showing how the intervention will progress to the next clinical trial phase and/or improve current standards of care after the successful completion of the FY24 ALSRP Pilot Clinical Trial Award.Milestone meeting: The Principal Investigator (PI) will be required to present an update on progress toward accomplishing the goals of the award at annual, virtual In Progress Review meetings to be held during the period of performance. The PI should ideally include their Community collaboration partner(s) in the meeting. The In Progress Review Meeting will be attended by members of the ALSRP Programmatic Panel, CDMRP staff, the USAMRAA Grants/Contracts Officer, and other stakeholders.

The DoD Arthritis, Focused Research Award is a funding opportunity aimed at supporting innovative, high-risk/high-reward arthritis research that could lead to significant discoveries or improvements in patient care and quality of life, with a particular emphasis on the impact of arthritis in the military and on women's health.

The Office of Science (SC) of the Department of Energy (DOE) hereby announces its continuing interest in receiving grant applications for support of work in the following program areas: Advanced Scientific Computing Research, Basic Energy Sciences, Biological and Environmental Research, Fusion Energy Sciences, High Energy Physics, Nuclear Physics, Isotope R and Production, and Accelerator R and Production. On September 3, 1992, DOE published in the Federal Register the Office of Energy Research Financial Assistance Program (now called the Office of Science Financial Assistance Program), 10 CFR 605, as a Final Rule, which contained a solicitation for this program. Information about submission of applications, eligibility, limitations, evaluation and selection processes and other policies and procedures are specified in 10 CFR 605.

This program provides funding to communities and Tribes at high risk of wildfires to develop protection plans and implement projects that reduce wildfire hazards and improve resilience.

The City of Arlington is accepting applications from public and non-profit agencies for projects that promote economic development and tourism in the City. Donor Name: City of Arlington State: County: All Counties Type of Grant: Grant Deadline: (mm/dd/yyyy) 06/28/2024 Size of the Grant: $100,000 to $500,000 Grant Duration: 1 Year Details: The funds can be used Qualifying events or projects; Tourism marketing  Marketing and operations of special events and festivals  Operations of tourism-related facilities owned by non-profit organizations  Operations and capital expenditures of tourism related facilities owned by municipalities Funding Information $175,000 is available for grants. Grant Period Funds are available on January 1, 2025, and must be spent by December 31, 2025. Who can apply? Open to any applicant that has a qualifying event or project All Applicants:  Completed Application Two letters of recommendation; each letter should explain the writer’s relationship to the project and/or sponsor, the writer’s qualifications for commenting on the project, and the writer’s opinion of the benefits of the proposed project. Copy of meeting minutes from the Board of Directors authorizing the submission of this application for Lodging Tax Funds. This does not apply to government agencies if the project/event is budgeted. A minimum 25% match (of total project costs) is required to be eligible to receive funding. Completed W-9. For more information, visit City of Arlington.

This funding opportunity supports a wide range of research projects in various scientific fields, providing financial assistance to universities, non-profits, and for-profit organizations to advance fundamental research that aligns with the Department of Energy's mission.

The City of La Porte’s Office of Community Development is currently seeking proposals for its Public Services Program funded through the federal Community Development Block Grant program. Donor Name: City of La Porte State: Indiana City: La Porte Type of Grant: Grant Deadline: 05/24/2024 Size of the Grant: Not Available Grant Duration: Grant Duration Not Mentioned Details: The Community Development Block Grant Program began in 2004 in the City of LaPorte.  Funded projects must meet one of the national objectives established by the Federal Department of Housing and Urban Development. These objectives are benefitting low- and moderate-income persons, preventing or eliminating slums or blight, or meeting other community needs having an urgency because existing conditions pose a serious and immediate threat to health or welfare of the community and other financial resources are not available to meet such needs. Proposed projects must be able to demonstrate a clear role in improving the quality of life for low- and moderate-income citizens of La Porte and must further the goals of self-sufficiency and self-reliance for La Porte residents. Funding Priorities  Homelessness — Objectives include the provision of services for: Coordination and outreach. Rental assistance. Supportive Services. Prevention. Non-housing Community Development — Objectives include: Provide support services to seniors, health services (including mental health), and emergency assistance. Support activities that promote self-reliance, employment, and education. Strengthen the capacity of local housing organizations by supporting fair housing outreach and education. Collaborate with local and regional institutions to ensure the availability of mortgages and insurance to all residents. Non-homeless Special Needs — Objectives include the provision of services for: Special needs coordination. Accessibility improvement. For more information, visit City of La Porte.

This grant invites government, academic, and industry collaborators to propose innovative research projects that enhance air warfare and weapons technology for the Navy and Marine Corps.

This funding opportunity is designed for research organizations affiliated with the Great Lakes Northern Forest Cooperative Ecosystem Studies Unit to study the growth and diet of alewife in Lake Michigan's nearshore areas, aiming to improve understanding of larval survival and population recruitment.

This funding opportunity is designed for partners affiliated with the Piedmont-South Atlantic Coast Cooperative Ecosystem Studies Unit to develop climate change data and strategies that support ecosystem and human health adaptation in the southeastern United States and the Caribbean.

This program provides funding to support the development of commercial direct air capture facilities and regional hubs, targeting innovators and companies working on advanced carbon capture technologies.

The "DoD Multiple Sclerosis, Early Investigator Research Award" is a grant designed to support early-stage researchers in developing a Multiple Sclerosis-focused research project under the guidance of experienced mentors, with the aim of advancing their careers and contributing to the understanding and treatment of Multiple Sclerosis.

The PWSA supports innovative research studies to advance research in preservation of function (physical ability), quality of life, symptom management, resilience, relief from neurocognitive deficits, and support for psychosocial issues related to cancer diagnosis, treatment, and survivorship. Studies must address one or more of these critical issues in at least one of the FY24 PRCRP Topic Areas. The overall intention of the PWSA is to fill gaps in the understanding of survivorship, including investigations into the psychological health and well-being of those affected by cancer (e.g., patients, family members). This may include investigations into studies that improve mental health and/or cancer-related outcomes in defined populations. Studies also may assess the relationship(s) between behavioral and social functioning in relation to cancer initiation, progression, detection, treatment, and rehabilitation. Applications may propose studies that examine preservation of function, quality-of-life, well-being, decision-making, and/or cognitive function, development and testing of educational interventions, and symptom management (e.g., toxicity of treatment, palliative/supportive care, psychological distress and anxiety) throughout treatment and beyond. Applications may target development of evidence-based practices, behavioral health science and patient well-being interventions and surveillance, and identification of psychosocial patient outcomes. Basic laboratory studies are not appropriate for the PWSA and may be withdrawn. The critical components of this award mechanism are: Impact: The PWSA is intended to support research that demonstrates the potential to have a major impact on patient well-being, outcomes, and health, including diagnosis, treatment, and after treatment. The proposed study must demonstrate how the research will transform outcomes related to at least one of the FY24 PRCRP Topic Areas. Research should challenge paradigms with respect to impact on patient care and outcomes. Proposed projects may include translational or clinical research, including pilot clinical trials. Impactful research will accelerate the movement of promising ideas into clinical applications and advance quality of life and survivorship. Study Design: Applications should clearly articulate the chosen design of the study. Studies entailing retrospective or prospective recruitment should define the type of architecture of the study (e.g., interventional, descriptive, correlational, field experimental, meta-analyses). Study populations should be clearly defined. The rationale should support the chosen study design with statistical evaluation to back the design. Questionnaires should be described in sufficient detail to justify interpretation of potential results. Studies utilizing animal models are not supported by this funding opportunity and may be withdrawn. Preliminary Data: The PWSA will require preliminary data for all studies that propose the active (prospective) recruitment of human subjects for pilot clinical trials. Studies not proposing active recruitment of human subjects are not required to present preliminary data but should be supported by sound reasoning and relevant literature. Patient Advocate Participation: Applications to the PWSA funding opportunity are required to include patient advocates. The research team must include at least one cancer patient advocate who will be integral throughout the planning and implementation of the research project. The patient advocate should be active in a cancer advocacy organization, have a high level of knowledge of current cancer issues, and be a representative from the FY24 PRCRP Topic Area(s) that is being studied. The patient advocate will be a person living with cancer; a person previously diagnosed with/treated for cancer but who now has no evidence of disease; or a family member or caretaker of someone with cancer. The patient advocate should be involved in the development of the research question, project design, oversight, and evaluation, as well as other significant aspects of the proposed project. Interactions with other team members should be well integrated and ongoing, not limited to attending seminars and semi-annual meetings. The role of the patient advocate should be focused on providing objective input on the research and its potential impact for individuals with or at risk for cancer.